Eli Lilly and Seamless Therapeutics Enter $1.12 Billion Collaboration to Develop Gene-Editing Therapies for Hearing Loss

Gelonghui January 28 | Eli Lilly and Company announced that it has signed an agreement worth up to $1.12 billion with German start-up Seamless Therapeutics GmbH to utilize the biotech company's gene-editing platform for developing and commercializing treatments for hearing loss.